Enlivex Therapeutics (NASDAQ:ENLV) Trading Down 14.1% – Here’s Why

Shares of Enlivex Therapeutics Ltd. (NASDAQ:ENLV) fell 14.1% during mid-day trading on Monday . The stock traded as low as $0.6651 and last traded at $0.6928. 668,741 shares were traded during mid-day trading, an increase of 119% from the average daily volume of 305,523 shares. The stock had previously closed at $0.8066.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on ENLV shares. Weiss Ratings reissued a “sell (d)” rating on shares of Enlivex Therapeutics in a research note on Friday, June 26th. Wall Street Zen upgraded shares of Enlivex Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 29th. Finally, Zacks Research raised shares of Enlivex Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 21st. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $247.50.

Enlivex Therapeutics Stock Performance

The company has a market cap of $11.19 million, a PE ratio of -0.08 and a beta of 1.42. The company’s 50-day simple moving average is $2.04 and its 200 day simple moving average is $8.52.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of ENLV. WINTON GROUP Ltd purchased a new position in shares of Enlivex Therapeutics in the 2nd quarter valued at about $55,000. Bank of America Corp DE increased its stake in shares of Enlivex Therapeutics by 53.2% during the first quarter. Bank of America Corp DE now owns 130,401 shares of the company’s stock worth $121,000 after buying an additional 45,303 shares during the period. Finally, Susquehanna International Group LLP raised its holdings in Enlivex Therapeutics by 1,428.5% in the second quarter. Susquehanna International Group LLP now owns 157,648 shares of the company’s stock valued at $87,000 after acquiring an additional 147,334 shares in the last quarter. 1.02% of the stock is owned by institutional investors and hedge funds.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd. is an Israel-based clinical-stage biotechnology company developing cell-based immunotherapies designed to restore immune-system balance, or immune homeostasis, in patients experiencing severe or dysregulated inflammation. The company focuses on conditions in which an excessive or impaired immune response may contribute to organ damage and other serious complications.

Its lead product candidate, Allocetra-OTS, is an off-the-shelf cell therapy made from healthy apoptotic cells.